

21ST ANNUAL
SAN DIEGO HEART FAILURE
SYMPOSIUM FOR
PRIMARY CARE AND
INTERNAL MEDICINE PHYSICIANS

NEW STRATEGIES FOR DETECTION,
PREVENTION AND
TREATMENT OF HEART FAILURE

JANUARY 29 & 30, 2021

A Virtual Event from
La Jolla, California

Sponsored by
UC San Diego Health
Cardiovascular Institute

A
Virtual
Event
with
LIVE Q&A

"Amazing,
learned
new things!"
TR

"Very
thorough and
organized..."
CS

"Wonderful;
very
informative!"
WM

Officially
Endorsed by



Arizona & California Chapters

COURSE DESCRIPTION

This year's 21st Annual San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians will use a virtual platform for providing an up to date analysis of new and emerging trends in the management of patients with heart failure. There have been numerous advances in heart failure over the past year and we plan to highlight the most important ones and to put them into the context of on-going management strategies. The topics included in this year's symposium include new approaches for modification of risk factors like hypertension, lipids and diabetes, a deep dive into the management of HFpEF and exciting new approaches for treating patients with amyloid heart disease, insights into newer drugs including the ARNIs, SGLT2 inhibitors, vericiguat, omecamtiv mecarbil and the potassium lowering agents as well as the expanding use of NOACs, role of biomarkers in heart failure management, an overview of devices to detect worsening of heart failure and the treatment of pulmonary arterial hypertension. There will also be updates on the most effective use of pacemakers, defibrillators and wearable devices, and percutaneous and durable mechanical support of the failing heart. We've had great success in weaving live panel and case discussions and Q/A panels into this year's agenda so that registrants will have the opportunity to interact with the internationally renowned faculty that will be presenting at the Symposium. In this way, the 21st Annual San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians will continue the tradition of the preceding ones in providing cutting edge information about heart failure by experts in the field in a format that enhances adaptation into clinical practice. We're looking forward to seeing you online on **January 29-30, 2021**.

TARGET AUDIENCE

This course is designed for cardiologists, internists, primary care physicians, nurses, PA's, PharmD's and all other allied healthcare professionals with an interest in heart failure.

ACCREDITATION

The AAFP has reviewed the 21st Annual San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians and deemed it acceptable for up to 7.75 Online Only, Live AAFP Prescribed credits. Term of Approval is from 01/29/2021 to 01/30/2021. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Approval for AAFP CME credit does not imply authorization to use the AAFP logo on CME activity materials or to use AAFP's name in any association with the activity other than the credit statement.

The AAFP reserves the right to perform a post - activity audit and / or have a live monitor at any AAFP certified CME activity.

AMA / AAFP Equivalency:

AAFP Prescribed credit is accepted by the American Medical Association as equivalent to **AMA PRA Category 1 Credit(s)**[™] toward the AMA Physician's Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.

SYMPOSIUM OBJECTIVES

At the conclusion of this program, the participant should be able to:

1. Summarize current and emerging treatments available for preventing and treating heart failure and provide information to help in the selection of the most effective choices in individual patients.
2. Review strategies for implementing medical and device therapies that will lead to improved outcomes in heart failure patients.
3. Define how specific populations including minorities, women and the elderly respond to various approaches to treating risk factors and heart failure.
4. Describe the impact of COVID-19 on the management of patients with heart failure.

NEEDS ASSESSMENT

Over five million Americans (two percent of the U.S.) are living with heart failure (HF). An estimated 670,000 new cases of HF are diagnosed each year and this condition is a major cause of morbidity and mortality (80% of men and 70% of women less than 65 years of age who have HF will die within 8 years) and is the number one cause of hospitalizations of the elderly in the U.S. HF is common, but unrecognized and often misdiagnosed. Recent data have shown that drugs and devices that have proven beneficial and are recommended in recent practice guidelines, (HFSA 2010 update of practice guidelines Lindelfield J et al J Cardiac Failure 2010;16; 475) are underutilized (Fonarow GC et al. Circulation 2010;122:585).

Recent information also suggests a significant individual variability in conformity to quality-of-care indicators and clinical outcome of patients with HF and a substantial gap in overall performance. In addition, according to a study analyzing the quality of health care in the U.S. on average, patients with heart failure received the recommended quality of care only 64% of the time (heart failure performance measurement set by the ACC/AHA 2010).

Despite important advances in treatment, patients with HF continue to experience unacceptably high rates of morbidity and mortality. This along with the enormous cost of caring for a growing number of HF patients has resulted in increased scrutiny of existing and emerging therapies.

Complete Symposium Information and online Registration:

SanDiegoHeartFailure.com



Officially endorsed by the Heart Failure Society of America. The opinions presented in this educational activity do not necessarily reflect the opinions or recommendations of the **HFSA**.

SYMPOSIUM CANCELLATIONS

If your registration must be cancelled and a refund of your fee is desired, your fee, less \$35 for administrative costs, will be refunded upon receipt of a written request that includes your signature. No refunds will be made after January 15, 2021. Please allow up to 12 weeks for a refund.

FURTHER INFORMATION

Complete Conference Management

3320 Third Avenue, Ste C San Diego, CA 92103

PH 619-299-6673 FAX 619-299-6675

info@ccmmeetings.com

www.ccmmeetings.com

FACULTY

UC SAN DIEGO PROGRAM DIRECTOR



Barry H. Greenberg, MD, FACC
Distinguished Professor of Medicine
Director, Advanced Heart Failure Treatment Program
UC San Diego
La Jolla, CA

GUEST FACULTY



Uri Elkayam, MD, FACC
Professor of Medicine, Division of Cardiology
University of Southern California
Keck School of Medicine
Los Angeles, CA



Gregg Fonarow, MD, FACC, FAHA, FHSA
Eliot Corday Professor of Cardiovascular Medicine and Science
Director, Ahmanson – UCLA Cardiomyopathy Center
Co-Director, UCLA Preventative Cardiology Program
Co-Chief of Clinical Cardiology, UCLA Division of Cardiology
David Geffen School of Medicine
Los Angeles, CA



John McMurray, MD
Professor of Medical Cardiology
BHF Cardiovascular Research Centre
University of Glasgow
Glasgow, Scotland
United Kingdom



Mandeep R. Mehra, MD, FACC, FESC, FHSA, FRCP (London)
The William Harvey Distinguished Chair in Advanced Cardiovascular Medicine
Executive Director, Center for Advanced Heart Disease
Professor of Medicine, Harvard Medical School
Editor in Chief, The Journal of Heart and Lung Transplantation
Brigham and Women's Hospital
Boston, MA



Scott Solomon, MD, FACC
The Edward D. Frohlich Distinguished Chair
Professor of Medicine, Harvard Medical School
Director, Noninvasive Cardiology
Senior Physician, Brigham and Women's Hospital
Boston, MA

FACULTY DISCLOSURE

It is our policy to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. All conflicts of interest will be resolved prior to an educational activity being delivered to learners through one of the following mechanisms 1) altering the financial relationship with the commercial interest, 2) altering the individual's control over CME content about the products or services of the commercial interest, and/or 3) validating the activity content through independent peer review. All persons are also required to disclose any discussions of off label/unapproved uses of drugs or devices. Persons who refuse or fail to disclose are disqualified from participating in the CME activity. Participants will be asked to evaluate whether the speaker's outside interests reflect a possible bias in the planning or presentation of the activity. This information is used to plan future activities.

UC SAN DIEGO PARTICIPATING FACULTY



Eric Adler, MD, FACC
Professor of Medicine
Medical Director,
Heart Transplant and MCS Program
Division of Cardiovascular Medicine



Demos Papamatheakis, MD
Associate Clinical Professor of Medicine
Division of Pulmonary, Critical Care
and Sleep Medicine



Cheryl A.M. Anderson, PhD, MPH, MS
Professor and Interim Chair in the
Department of Family and Public Health



Ryan Reeves, MD, FACC
Associate Professor of Medicine
Interventional Cardiology



Saima Aslam, MD, MS
Associate Professor of Medicine Medical
Director, Solid Organ Transplant
Infectious Diseases
Division of Infectious Diseases and
Global Public Health



Jia Shen, MD, MPH
Assistant Clinical Professor of Medicine
Department of Cardiovascular
Diseases



Ulrika Birgersdotter-Green, MD
Professor of Medicine
Division of Cardiology
Director, Pacemaker and ICD Services



Jorge Silva Enciso, MD
Associate Clinical Professor of Medicine
Director, Hypertrophic
Cardiomyopathy Program
Heart Failure, Mechanical
Circulatory Support and
Transplant Cardiology



Lori Daniels, MD, MAS, FACC, FAHA
Professor of Medicine
Director, Cardiovascular Intensive
Care Unit



Pam R. Taub, MD, FACC, FASPC
Associate Professor of Medicine
Director of Step Family Foundation
Cardiovascular Rehabilitation and
Wellness Center



Christian W. Mende, MD
Clinical Professor of Medicine
Department of Nephrology



Howie Tran, MD, FACC
Assistant Clinical Professor of Medicine
Heart Failure and Transplant
Cardiology



Robert L. Owens, MD
Assistant Professor of Medicine
Division of Pulmonary, Critical Care and
Sleep Medicine



Marcus Anthony Urey, MD
Assistant Clinical Professor of Medicine
Division of Cardiovascular Medicine

FRIDAY, JANUARY 29

12:00pm	Product Theatre I - (Non-CME)
1:05pm	Welcome & Introduction to the Symposium - Barry Greenberg, MD
SESSION I	Risk Factors and Prevention
1:10pm	Barry Greenberg, MD (Moderator) – Introduction of Session Speakers
1:15-1:30	Managing Patients Hypertension During the COVID-19 Era Chris Mende, MD
1:30-1:45	Lipid Lowering from Statins and PSK9 Inhibitors to New Agents Pam Taub, MD
1:45-2:00	Approaches to Treating Diabetes that Reduce Cardiovascular Events Jia Shen, MD
2:00-2:15	Are Biomarkers Helpful in Identifying Patients at Risk for Heart Failure? Lori Daniels, MD
2:15-2:30	Q/A and Panel Discussion Pam Taub, MD (Moderator) - Drs. Mende and Daniels (Panelists)
2:40-3:40	Product Theatre II - (Non-CME)
SESSION II	Cardiac Hypertrophy, Amyloid and Other Infiltrative Diseases
3:50pm	Marcus Anthony Urey, MD (Moderator) – Introduction of Session Speakers
3:55-4:10	Recognizing and Treating HFpEF Barry Greenberg, MD
4:10-4:25	Hypertrophic Cardiomyopathy – Advances in Diagnosis and Treatment Jorge Silva Enciso, MD
4:25-4:40	Advances in the Management of Amyloid Disease Marcus Anthony Urey, MD
4:40-4:55	Case Discussion - Marcus Anthony Urey, MD (Presenter) Drs. Greenberg, Silva Enciso (Panelists)
4:55	Adjourn Day 1

SATURDAY, JANUARY 30

7:20am	Welcome to Day 2 - Barry Greenberg, MD (Program Chair)
SESSION III	Focus on COVID-19 and Disparities in Care
7:25am	Barry Greenberg, MD (Moderator) – Introduction of Session Speakers
7:30-7:50	FEATURED PRESENTATION Treating COVID-19 and Controlling the Pandemic: Where Do We Stand? Saima Aslam, MD
7:50-8:05	Cardiovascular Effects of COVID-19 Eric Adler, MD
8:05-8:25	Role of the Renin Angiotensin System in Coronavirus Infections Barry Greenberg, MD
8:25-8:40	Recognizing and Mitigating Disparities in Care During the Pandemic Cheryl Anderson, MD
8:40-8:55	Q/A and Panel Discussion Dr. Greenberg (Moderator) - Drs. Aslam, Adler and Anderson (Panelists)
9:00-10:00	Product Theatre III - (Non-CME)
10:00-10:10	Break/Visit Virtual Exhibits

SATURDAY, JANUARY 30 *(continued)*

SESSION IV

Advances in Heart Failure Management

10:10am

Howie Tran, MD (*Moderator*) – Introduction of Session Speakers

10:15-10:30

Expanding the Role of ARNI's Across the Heart Failure Continuum
Scott Solomon, MD

10:30-10:45

SGLT2 Inhibitors as First-Line Therapy for Heart Failure
John McMurray, MD

10:45-11:00

The New Kids on the Block – Vericiguat, Omecamtiv, mecarbil and IV Iron
Barry Greenberg, MD

11:00-11:15

Treating Hyperkalemia – Why and How
Uri Elkayam, MD

11:15-11:30

Learning from CHAMP-HF: How Can We Improve Drug Therapy?
Gregg Fonarow, MD

11:30-11:45

Management of Sleep Disordered Breathing
Robert Owens, MD

11:45-12:00

Q/A and Panel Discussion
Howie Tran, MD (*Moderator*) - Drs. McMurray, Solomon, Greenberg Elkayam, Fonarow and Owens (*Panelists*)

12:10-1:10

Product Theatre IV

SESSION V

Biomarkers and Devices to Detect and Treat Heart Failure

1:15pm

Ulrika Birgersdotter Green, MD (*Moderator*) – Introduction of Session Speakers

1:20-1:35

Biomarkers to Detect, Risk Stratify and Guide Therapy of Heart Failure
Lori Daniels, MD

1:35-1:50

Devices for Detecting Worsening Heart Failure
Howie Tran, MD

1:50-2:05

Devices for Preventing Stroke in Patients with Atrial Fibrillation
Ryan Reeves, MD

2:05-2:20

What's New in Pacemakers, Defibrillators, CRT
Ulrika Birgersdotter Green, MD

2:20-2:35

Q/A and Panel Discussion
Ulrika Birgersdotter Green, MD (*Moderator*), Drs. Tran, Reeves (*Panelists*)
Break/Visit Virtual Exhibits

2:35-2:45

SESSION VI

Recognizing and Treating Advanced Heart Failure

2:45pm

Barry Greenberg, MD (*Moderator*) – Introduction of Session Speakers

2:45-3:00

Detecting and Treating Pulmonary Arterial Hypertension
Demos Papamatheakis, MD

3:00-3:15

Recognizing and Referring Patients for Advanced Heart Failure Therapies
Eric Adler, MD

3:15-3:30

Advances in Temporary Mechanical Support of Acute Heart Failure
Ryan Reeves, MD

3:30-3:45

Left Ventricular Assist Devices - Patient Selection and Outcomes
Mandeep Mehra, MD

3:45

Adjourn until January, 2022

REGISTRATION

21ST ANNUAL SD HEART FAILURE SYMPOSIUM

First Name _____

Last Name _____

Title _____

Office Address _____

City _____

State _____ Zip _____

Phone _____

Fax _____

Email _____

Professional Specialty _____

Special Needs for Disabled _____

Registration Fees:

Physicians

\$99 Early Bird Registration – on or before December 31, 2020

\$139 Registration – on or after January 1, 2021

Nurse/Allied Health Care

\$69 Early Bird Nurse/Allied Health – on or before December 31, 2020

\$99 Registration Nurse/Allied Health – on or after January 1, 2021

Fellow/Residents/Students*

\$69 Early Bird – on or before December 31, 2020

\$99 Registration – on or after January 1, 2021

**Student/Fellow with letter of verification*

CREDIT CARD PAYMENT - Visa, Mastercard, Discover or Am Ex ONLY

Name on Card _____

Card Number _____

Security Code _____ Exp. Date _____

Billing Address _____

Amount \$ _____

Signature _____

CHECK OR MONEY ORDER PAYMENT (in US dollars)

Make payable to:

UC Regents

*Please do not send credit
card information by fax.*

Send or to:

**Complete Conference Management
3320 Third Avenue, Suite C
San Diego, CA 92103
Fax: 619-299-6675**